While there is potential for dasatinib-AKT inhibitor combinations to be useful clinically, the similar level of synergy in both WT and CDH1−/− cells suggests that this combination may not increase the available therapeutic index between normal cells and early CDH1-null cancers. Here, CDH1 is linked to cancer.